Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that its President and CEO, Antony Mattessich, will participate in a fireside chat at Cowen’s 43rd Annual Healthcare Conference on March 7, 2023, at 1:30 PM EST. Investors wishing to meet with Ocular Therapeutix management during the conference should contact their Cowen representative. A live webcast of the presentation will be available on the company’s website.
The company focuses on developing innovative therapies for eye diseases and conditions, including DEXTENZA®, an FDA-approved corticosteroid. It is also advancing multiple assets in clinical trials for various eye conditions.
- None.
- None.
BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at Cowen’s 43rd Annual Healthcare Conference on Tuesday, March 7, 2023 at 1:30 PM EST.
In addition to the presentation, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Cowen representative.
A live webcast of the presentation can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and diabetic retinopathy; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials.
Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com
or
ICR Westwicke
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
FAQ
What event will Ocular Therapeutix participate in on March 7, 2023?
Who is presenting for Ocular Therapeutix at the conference?
What is the primary focus of Ocular Therapeutix?
Where can I watch the Ocular Therapeutix presentation live?
What is DEXTENZA®?
